Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Colorcon
Healthtrust
UBS
Argus Health
US Department of Justice
Boehringer Ingelheim
Teva
Deloitte

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,351,834

« Back to Dashboard

Summary for Patent: 7,351,834
Title:.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy (Hyogo, JP), Scott; William (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert (North Haven, CT)
Assignee: Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:09/889,227
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,351,834
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,351,834

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,351,834

PCT Information
PCT FiledJanuary 12, 2000PCT Application Number:PCT/US00/00648
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/42012

Non-Orange Book US Patents Family Members for Patent 7,351,834

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,928,239 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas ➤ Sign Up
7,528,255 Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors ➤ Sign Up
8,841,330 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Sign Up
8,124,630 .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
Dow
Harvard Business School
Medtronic
US Department of Justice
McKinsey
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.